Androgen-responsive kinases, which are upregulated, present as targets to reduce the proliferation of AR-dependent prostate cancer, and downregulated kinases imply changes that can occur during ADT and, thus, may be therapeutic targets for reducing the progression of androgen independence of prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.